13 results about "Infective Agent" patented technology

Described herein are compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and a nucleic acid sequence (e.g., mRNA) encoding at least one universal T-cell epitope (UTE), as well as compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope, and methods for using the compositions.

Provided herein are vaccine compositions for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology. The composition comprises IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family. Further contemplated herein are compositions and methods of stimulating germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.

Embodiments of the present disclosure are directed to systems and methods for collection and analysis of environmental air dust (EAD) within an individually ventilated cage rack (IVR) environment for detecting pathogens. The method includes collection of an EAD sample by a collection media, isolation of a plurality of nucleic acids (e.g., RNA and / or DNA) representative of one or more infectious agents from the EAD sample, optional reverse transcription of RNA to cDNA if the isolated nucleic acids contain RNA, amplification of the cDNA and / or DNA (e.g., by polymerase chain reaction (PCR)), and assay interpretation. Optionally, the EAD sample may be analyzed with one or more other sample types (e.g., fecal pellets, oral swabs, body swabs, tissue, etc.) to improve detection of low-copy organisms.

Provided are a Lactobacillus plantarum against Helicobacter pylori infection and the use thereof. The Lactobacillus plantarum against Helicobacter pylori infection is named Lactobacillus plantarum Lp05 and was deposited in the China General Microbiological Culture Collection Center on 9 Oct. 2021, with the deposit number CGMCC No. 23547. Further provided are a method for culturing the Lactobacillus plantarum against Helicobacter pylori infection and a product for inhibiting Helicobacter pylori infection. The Lactobacillus plantarum against Helicobacter pylori infection of the present application has good gastric acid resistance, inhibits the proliferation of Helicobacter pylori, and reduces the adhesion effect of Helicobacter pylori to gastric epithelial cells, thereby creating conditions for the eradication of Helicobacter pylori. The product for inhibiting Helicobacter pylori infection does not cause adverse reactions nor drug resistance of pathogenic bacteria.

The present disclosure relates to methods for assessing host DNA damage in samples exposed to infectious agents using antimicrobial-modified comet assay. The disclosure further relates to a modified comet assay configured to assess DNA damage while eliminating interference caused by infectious agents. The methods extend conventional comet assay use beyond chemical genotoxin screening to infection related damage profiling and quality controlled antimicrobial testing.

Metal nanoparticle agglomerates in various forms may be utilized to promote infection control. Antiseptic substrates may comprise a base substrate and metal nanoparticle agglomerates adhered thereto. Metal nanoparticle agglomerates upon the antiseptic substrates may be contacted with a skin penetration, a skin injury, a burn, a site to be subjected to a skin penetration, or an active skin infection to provide infection control against at least one infective agent. The antiseptic substrates may also facilitate water purification in some cases. Antiseptic fluid formulations comprising a fluid medium having metal nanoparticle agglomerates dispersed therein may be configured for topical or oral use and may similarly afford infection control. Creams, ointments, balms, salves, gels, and liquids or liquid suspensions containing metal nanoparticle agglomerates may be effective for promoting infection control and / or for treating an active infection.

The invention discloses a method for screening fat key genes through whole genome knockout, and relates to the technical field of biology. According to the invention, a whole genome knockout system suitable for chicken preadipocyte lines (ICP) is established based on a strategy of improving lentivirus infection efficiency by a cationic co-infection agent, and lipid droplet phenotype screening is carried out in combination with flow cytometry SSC signals, so that key genes influencing fat deposition can be efficiently and systematically screened; and a new technical platform is provided for poultry fat metabolism research and low-fat breeding. Functional verification is performed on the CYP46A1 gene screened based on the system, and results show that after the gene is knocked out, lipid droplet accumulation of chicken preadipocytes is remarkably reduced, expression of lipid metabolism key genes is reduced, and the effect of the CYP46A1 gene in fat deposition regulation is defined.

Flow cytometry is used for diagnosis of infectious diseases by an analysis of cell mediated immune responses to specific infective agent antigens. Apparatus and methods of advanced flow cytometry are utilized to detect cell mediated immune responses to the presence of specific antigens from infective agents, such as bacteria, protozoa, viruses, helminth, prions. In some embodiments, methods as provided herein can be utilized in vitro to diagnose multiple infections within individuals.

To provide a compound having antibacterial activity. [Solution] The present invention relates to a novel oxazolidinone (formula I) having ring A characterized by a monocyclic, bicyclic, or spirocyclic substituent containing nitrogen. The present invention relates to TIFF2026092059000321.tif3764 or pharmaceutically acceptable salts thereof, their preparations, and their use alone or in combination with other anti-infective agents as drugs for treating Mycobacterium tuberculosis and other microbial infections. The present invention generally relates to compounds having antibacterial activity, more specifically, anti-tuberculosis properties. In particular, the present invention relates to substituted phenyloxazolidinone compounds useful for treating tuberculosis in patients requiring treatment for tuberculosis.

The invention relates to a molecular system comprising: (i) at least one dynamic constitutional framework (DCF) comprising a plurality of cores and a plurality of connectors, (ii) a plurality of functional heads, (iii) at least one pillararene and, optionally, (iv) at least one anti-infective agent; wherein each of the anti-infective agents is hosted in one of the pillararenes; wherein the cores, connectors, functional heads, and pillararenes are covalently bound together by reversible bonds; and wherein each of the cores is covalently bound to at least three from the connectors, functional heads and pillararenes. The invention also relates to a pharmaceutical composition or medicament comprising the molecular system. The invention also relates to the molecular system for use in the treatment of an infectious disease such as a bacterial disease, preferably a disease caused by Acinetobacter baumannii bacteria.

The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and / or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and / or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.